Europe Adalimumab Market - Industry Trends and Forecast to 2029

TABLE OF CONTENT

TABLE OF CONTENTS
1 INTRODUCTION 17
1.1 OBJECTIVES OF THE STUDY 17
1.2 MARKET DEFINITION 17
1.3 OVERVIEW OF EUROPE ADALIMUMAB MARKET 17
1.4 LIMITATIONS 19
1.5 MARKETS COVERED 19
2 MARKET SEGMENTATION 21
2.1 MARKETS COVERED 21
2.2 GEOGRAPHICAL SCOPE 22
2.3 YEARS CONSIDERED FOR THE STUDY 22
2.4 CURRENCY AND PRICING 22
2.5 DBMR TRIPOD DATA VALIDATION MODEL 23
2.6 MULTIVARIATE MODELLING 26
2.7 INDICATION LIFELINE CURVE 26
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 27
2.9 DBMR MARKET POSITION GRID 28
2.10 MARKET END USER COVERAGE GRID 29
2.11 VENDOR SHARE ANALYSIS 30
2.12 SECONDARY SOURCES 31
2.13 ASSUMPTIONS 31
3 EXECUTIVE SUMMARY 32
4 PREMIUM INSIGHTS 35
4.1 PESTEL 36
4.2 PORTER'S FIVE FORCES MODEL 37
5 PIPELINE ANALYSIS 38
6 EPIDEMIOLOGY 39
7 EUROPE ADALIMUMAB MARKET: REGULATIONS 40
7.1 REGULATION IN EUROPE: 40
8 IMPACT OF BIOSIMILAR 42

9 IMPACT OF COVID-19 ON EUROPE ADALIMUMAB MARKET 43
9.1 OVERVIEW 43
9.2 ADALIMUMAB AND COVID-19 43
9.3 PRICE IMPACT OF COVID-19 43
9.4 IMPACT ON DEMAND 44
9.5 IMPACT ON SUPPLY CHAIN 44
9.6 STRATEGIC DECISIONS FOR MANUFACTURERS 44
9.7 CONCLUSION 45
10 MARKET OVERVIEW 46
10.1 DRIVERS 48
10.1.1 INCREASE IN PREVALENCE OF RHEUMATOID ARTHRITIS 48
10.1.2 INCREASE IN THE GERIATRIC POPULATION 48
10.1.3 INCREASE IN THE NUMBER OF CONTRACT RESEARCH ORGANIZATIONS 49
10.2 RESTRAINTS 49
10.2.1 HIGH COST OF DRUGS 49
10.2.2 SIDE EFFECTS OF DRUGS 50
10.2.3 CANCER-CAUSING DRUGS 50
10.3 OPPORTUNITIES 51
10.3.1 RISING HEALTHCARE EXPENDITURE 51
10.3.2 STRATEGIC INITIATIVES BY MARKET PLAYERS 51
10.3.3 PRESENCE OF PRODUCT PIPELINE 52
10.4 CHALLENGES 52
10.4.1 LONG APPROVAL PROCEDURE 52
10.4.2 AVAILABILITY OF ALTERNATIVE DRUGS 53
11 EUROPE ADALIMUMAB MARKET, BY INDICATION 55
11.1 OVERVIEW 56
11.2 RHEUMATOID ARTHRITIS 59
11.3 ANKYLOSING SPONDYLITIS 59
11.4 CHRONIC PLAQUE PSORIASIS 60
11.5 CROHN'S DISEASE 60
11.6 ULCERATIVE COLITIS 60
11.7 PSORIATIC ARTHRITIS 61
11.8 JUVENILE IDIOPATHIC ARTHRITIS 61
11.9 HIDRADENITIS SUPPURATIVA 62
11.10 NON-INFECTIOUS INTERMEDIATE 62
11.11 OTHERS 63

12 EUROPE ADALIMUMAB MARKET, BY TYPE 64
12.1 OVERVIEW 65
12.2 BIOLOGICS 67
12.3 BIOSIMILARS 68
12.3.1 ADALIMUMAB-ATTO 68
12.3.2 ADALIMUMAB-ADAZ 68
12.3.3 ADALIMUMAB-FKJP 68
12.3.4 OTHERS 69
13 EUROPE ADALIMUMAB MARKET, BY DOSAGE STRENGTH 70
13.1 OVERVIEW 71
13.2 40MG/0.8ML 73
13.3 20MG/0.4ML 74
13.4 OTHERS 74
14 EUROPE ADALIMUMAB MARKET, BY DRUG TYPE 75
14.1 OVERVIEW 76
14.2 HUMIRA 78
14.3 AMGEVITA 78
14.4 IMRALDI 79
14.5 HYRIMOZ 79
14.6 YUFLYMA 79
14.7 HULIO 79
14.8 IDACIO 79
15 EUROPE ADALIMUMAB MARKET, BY POPULATION TYPE 80
15.1 OVERVIEW 81
15.2 ADULTS 83
15.3 CHILDREN 84
16 EUROPE ADALIMUMAB MARKET, BY END USER 85
16.1 OVERVIEW 86
16.2 HOSPITALS 88
16.3 SPECIALTY CLINICS 89
16.4 HOME HEALTHCARE 89
16.5 OTHERS 90

17 EUROPE ADALIMUMAB MARKET, BY DISTRIBUTION CHANNEL 91
17.1 OVERVIEW 92
17.2 HOSPITAL PHARMACIES 94
17.3 RETAIL PHARMACIES 95
17.4 ONLINE PHARMACIES 95
17.5 OTHERS 96
18 EUROPE 97
18.1 GERMANY 106
18.2 U.K. 108
18.3 ITALY 110
18.4 FRANCE 112
18.5 SPAIN 114
18.6 NETHERLANDS 116
18.7 SWITZERLAND 118
18.8 RUSSIA 120
18.9 BELGIUM 122
18.10 TURKEY 124
18.11 AUSTRIA 126
18.12 NORWAY 128
18.13 HUNGARY 130
18.14 LITHUANIA 132
18.15 IRELAND 134
18.16 POLAND 136
18.17 REST OF EUROPE 138
19 EUROPE ADALIMUMAB MARKET: COMPANY LANDSCAPE 139
19.1 COMPANY SHARE ANALYSIS: EUROPE 139
20 SWOT ANALYSIS 140
21 COMPANY PROFILE 141
21.1 ABBVIE INC. 141
21.1.1 COMPANY SNAPSHOT 141
21.1.2 REVENUE ANALYSIS 141
21.1.3 PRODUCT PORTFOLIO 142
21.1.4 RECENT DEVELOPMENTS 142

21.2 AMGEN INC. 143
21.2.1 COMPANY SNAPSHOT 143
21.2.2 REVENUE ANALYSIS 143
21.2.3 PRODUCT PORTFOLIO 144
21.2.4 RECENT DEVELOPMENT 144
21.3 BIOGEN 145
21.3.1 COMPANY SNAPSHOT 145
21.3.2 REVENUE ANALYSIS 145
21.3.3 PRODUCT PORTFOLIO 146
21.3.4 RECENT DEVELOPMENT 146
21.4 SANDOZ INTERNATIONAL GMBH 147
21.4.1 COMPANY SNAPSHOT 147
21.4.2 REVENUE ANALYSIS 147
21.4.3 PRODUCT PORTFOLIO 147
21.4.4 RECENT DEVELOPMENTS 147
21.5 CELLTRION HEALTHCARE CO., LTD. 148
21.5.1 COMPANY SNAPSHOT 148
21.5.2 REVENUE ANALYSIS 148
21.5.3 PRODUCT PORTFOLIO 149
21.5.4 RECENT DEVELOPMENTS 149
21.6 MYLAN N.V. (A SUBSIDIARY OF VAITRIS INC.) 150
21.6.1 COMPANY SNAPSHOT 150
21.6.2 REVENUE ANALYSIS 150
21.6.3 PRODUCT PORTFOLIO 151
21.6.4 RECENT DEVELOPMENTS 151
21.7 ALVOTECH 152
21.7.1 COMPANY SNAPSHOT 152
21.7.2 PRODUCT PORTFOLIO 152
21.7.3 RECENT DEVELOPMENT 152
21.8 BIOCAD 153
21.8.1 COMPANY SNAPSHOT 153
21.8.2 PRODUCT PORTFOLIO 153
21.8.3 RECENT DEVELOPMENTS 153
21.9 COHERUS BIOSCIENCES 154
21.9.1 COMPANY SNAPSHOT 154
21.9.2 PRODUCT PORTFOLIO 154
21.9.3 RECENT DEVELOPMENTS 154

21.10 FRESENIUS KABI SWISSBIOSIM GMBH 155
21.10.1 COMPANY SNAPSHOT 155
21.10.2 PRODUCT PORTFOLIO 155
21.10.3 RECENT DEVELOPMENTS 155
21.11 JANSSEN GLOBAL SERVICES, LLC 156
21.11.1 COMPANY SNAPSHOT 156
21.11.2 PRODUCT PORTFOLIO 156
21.11.3 RECENT DEVELOPMENTS 156
21.12 PRESTIGE BIOPHARMA LTD. 157
21.12.1 COMPANY SNAPSHOT 157
21.12.2 PRODUCT PORTFOLIO 157
21.12.3 RECENT DEVELOPMENT 157
21.13 SHANGHAI HENLIUS BIOTECH, INC. 158
21.13.1 COMPANY SNAPSHOT 158
21.13.2 PRODUCT PORTFOLIO 158
21.13.3 RECENT DEVELOPMENT 158
21.14 SYNERMORE BIOLOGICS 159
21.14.1 COMPANY SNAPSHOT 159
21.14.2 PRODUCT PORTFOLIO 159
21.14.3 RECENT DEVELOPMENTS 159
22 QUESTIONNAIRE 160
23 RELATED REPORTS 163